This research has come from a detailed analysis of about 43 million people aged 13 years and above.
The study found that a single dose of the vaccine is 76% effective at protecting from primary symptomatic COVID-19 for the first 90 days post-vaccination.
The European Commission on Friday gave a green light to AstraZeneca/Oxford vaccine for people 18 years and above.
The entire country is indebted to all scientists and technicians," PM Modi said while addressing the National Metrology Conclave via video conferencing.
Covishield, the vaccine developed by Oxford University and pharma major AstraZeneca has been given a heads up by the expert panel for emergency use in India.
The final-stage trial results, published in The Lancet journal, confirmed that the Oxford-AstraZeneca COVID-19 vaccine works in an average of 70 per cent of cases.
Currently, Serum Institute of India (SII) is conducting phase 2 and 3 trials of the Astrazeneca-Oxford vaccine at various centres across the country.
Pfizer and BioNTech are planning to produce up to 100 million doses of the vaccine by the end of 2020 and another 1.2 billion doses by the end of 2021.
Serum Institute is preparing to manufacture 200 million doses of Oxford-AstraZeneca coronavirus vaccine, which will be called Covishield in India.
Results of the initial clinical trials of Oxford-AstraZeneca vaccine are out. Here are some key points from the Phase I/II study.
This research has come from a detailed analysis of about 43 million people aged 13 years and above.
The study found that a single dose of the vaccine is 76% effective at protecting from primary symptomatic COVID-19 for the first 90 days post-vaccination.
The European Commission on Friday gave a green light to AstraZeneca/Oxford vaccine for people 18 years and above.
The entire country is indebted to all scientists and technicians," PM Modi said while addressing the National Metrology Conclave via video conferencing.
Covishield, the vaccine developed by Oxford University and pharma major AstraZeneca has been given a heads up by the expert panel for emergency use in India.
The final-stage trial results, published in The Lancet journal, confirmed that the Oxford-AstraZeneca COVID-19 vaccine works in an average of 70 per cent of cases.
Currently, Serum Institute of India (SII) is conducting phase 2 and 3 trials of the Astrazeneca-Oxford vaccine at various centres across the country.
Pfizer and BioNTech are planning to produce up to 100 million doses of the vaccine by the end of 2020 and another 1.2 billion doses by the end of 2021.
Serum Institute is preparing to manufacture 200 million doses of Oxford-AstraZeneca coronavirus vaccine, which will be called Covishield in India.
Results of the initial clinical trials of Oxford-AstraZeneca vaccine are out. Here are some key points from the Phase I/II study.
